Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosis
Authors
Tamera J. Corte
Felix Woodhead (ORCID: https://orcid.org/0000-0003-3305-9001)
Howard M. Lazarus (ORCID: https://orcid.org/0000-0001-8231-3710)
Colin Reisner (ORCID: https://orcid.org/0000-0003-1856-9863)
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosis
Tamera J. Corte, Felix Woodhead, Howard M. Lazarus, Colin Reisner et al.
Journal
BMJ Open Respiratory Research
Topics
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
article
Design of the MIST study: a double-blind, randomised, placebo-controlled phase 2b trial of pirfenidone solution for inhalation in patients with progressive pulmonary fibrosis
Tamera J. Corte, Felix Woodhead, Howard M. Lazarus, Colin Reisner, Deepthi Nair, Martin Kolb, Craig Conoscenti, Steven D Nathan, Jeremy Feldman
article en
Abstract
No abstract available for this paper.
Publication Tag
BMJ Open Respiratory ResearchVol. 12(1)
Institutions
The University of Sydney (AU), Royal Prince Alfred Hospital (AU), Inova Fairfax Hospital (US), Athira Pharma (United States) (US), Institute for Respiratory Health (AU), Oregon State University Cascades (US)
OpenAlex Percentile
Openalex Percentile: Top 28%
Topics
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis